Emily Bodnar, an analyst from H.C. Wainwright, reiterated the Buy rating on SAB Biotherapeutics. The associated price target remains the same with $9.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Emily Bodnar’s rating is based on the promising developments surrounding SAB Biotherapeutics’ SAB-142, which were highlighted at the European Association for the Study of Diabetes symposium. The company presented encouraging preclinical and Phase 1 data for SAB-142, showcasing its potential as a best-in-class immunotherapy for preventing new-onset Stage 3 Type 1 Diabetes. The drug’s multi-specific mechanism of action promotes sustained immunomodulation, which is a significant advantage over existing treatments.
Furthermore, the initiation of the Phase 2b SAFEGUARD trial and strategic partnerships with organizations like the Australasian T1D Immunotherapy Collaborative and INNODIA are expected to enhance patient enrollment and advance the development of SAB-142. The positive safety and efficacy profile demonstrated in earlier studies, along with anticipated additional data, bolster confidence in the drug’s potential. These factors collectively contribute to the Buy rating, as they indicate a strong potential for future success and market impact.
According to TipRanks, Bodnar is an analyst with an average return of -1.3% and a 35.91% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as Agenus, Atossa Therapeutics, and Agios Pharma.
In another report released on September 17, Leerink Partners also initiated coverage with a Buy rating on the stock with a $7.00 price target.